Icrucumab Human Monoclonal Antibody
Icrucumabis a research-grade recombinant antibody targeting FLT1. Produced in mammalian cells with native-like glycosylation. Highlights Research Grade: For PK/PD studies, assay development, and ADA research. Native Glycosylation: Mammalian expression ensures native-like patterns.
Product Specifications
Product Name Alternative
FLT1, Vascular endothelial growth factor receptor 1, VEGFR1, Vascular permeability factor receptor, FRT, Tyrosine-protein kinase receptor FLT, VEGFR-1, FLT, FLT-1, Tyrosine-protein kinase FRT, Fms-like tyrosine kinase 1
UniProt
P17948
Reactivity
Human
Clonality
Monoclonal
Conjugation
Unconjugated
Purification
Protein A/G purified from cell culture supernatant.
Concentration
Lot dependent
Purity
>95% purity as determined by SDS-PAGE.
Form
Liquid
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Tested Applications
ELISA, FA, FACS, In vivo
Host or Source
Human
Preservative
0.01M PBS, pH 7.4.
Isotype
IgG1-kappa
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040965-500 1x 500 µL
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (VU-11D1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740523-100 1x 100 µL
AFP (Alpha Fetoprotein) (C2), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC471492-500 1x 500 µL
PAX8 (Renal Cell Marker) (PAX8/1492), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 